| Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial M Toulmonde, N Penel, J Adam, C Chevreau, JY Blay, A Le Cesne, ... JAMA oncology 4 (1), 93-97, 2018 | 409 | 2018 |
| A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1) H Bonnefoi, T Grellety, O Tredan, M Saghatchian, F Dalenc, A Mailliez, ... Annals of Oncology 27 (5), 812-818, 2016 | 307 | 2016 |
| Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort A Italiano, A Bessede, M Pulido, E Bompas, S Piperno-Neumann, ... Nature medicine 28 (6), 1199-1206, 2022 | 177 | 2022 |
| Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label … M Toulmonde, M Pulido, I Ray-Coquard, T André, N Isambert, ... The Lancet Oncology 20 (9), 1263-1272, 2019 | 169 | 2019 |
| Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study A Le Cesne, P Marec-Berard, JY Blay, N Gaspar, F Bertucci, N Penel, ... European journal of cancer 119, 151-157, 2019 | 156 | 2019 |
| Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or without resection S Evrard, M Rivoire, JP Arnaud, E Lermite, C Bellera, M Fonck, ... Journal of British Surgery 99 (4), 558-565, 2012 | 83 | 2012 |
| Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for … CA Bellera, M Pulido, S Gourgou, L Collette, A Doussau, A Kramar, ... European journal of cancer 49 (4), 769-781, 2013 | 77 | 2013 |
| Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicentre prospective study F Bonichon, J Palussière, Y Godbert, M Pulido, E Descat, A Devillers, ... European journal of nuclear medicine and molecular imaging 40, 1817-1827, 2013 | 50 | 2013 |
| A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration-resistant prostate cancer N Houédé, M Pulido, L Mourey, F Joly, JM Ferrero, C Bellera, F Priou, ... The oncologist 19 (12), 1227-1228, 2014 | 49 | 2014 |
| Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced … N Quenel-Tueux, M Debled, J Rudewicz, G MacGrogan, M Pulido, ... British Journal of Cancer 113 (4), 585-594, 2015 | 35 | 2015 |
| Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study M Toulmonde, M Brahmi, A Giraud, C Chakiba, A Bessede, M Kind, ... Clinical Cancer Research 28 (9), 1765-1772, 2022 | 28 | 2022 |
| Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer M Pulido, G Roubaud, AL Cazeau, H Mahammedi, L Vedrine, F Joly, ... BMC cancer 18, 1-9, 2018 | 26 | 2018 |
| Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer J Mathiaux, V Le Morvan, M Pulido, J Jougon, H Bégueret, J Robert Molecular diagnosis & therapy 15, 159-166, 2011 | 26 | 2011 |
| Enhancing abiraterone acetate efficacy in androgen receptor–positive triple-negative breast cancer: Chk1 as a potential target T Grellety, C Callens, E Richard, A Briaux, V Vélasco, M Pulido, ... Clinical Cancer Research 25 (2), 856-867, 2019 | 23 | 2019 |
| PALOMAGE, a French real-world cohort of elderly women beyond age 70 with advanced breast cancer receiving palbociclib: Baseline characteristics and safety evaluation. P Caillet, M Pulido, E Brain, C Falandry, I Desmoulins, D Ghebriou, ... Journal of Clinical Oncology 39 (15_suppl), 1012-1012, 2021 | 22 | 2021 |
| Cabozantinib in patients with advanced osteosarcomas and Ewing sarcomas: a French Sarcoma Group (FSG)/US National Cancer Institute phase II collaborative study A Italiano, N Penel, M Toulmonde, E Bompas, S Piperno-Neumann, ... Annals of Oncology 29, viii753, 2018 | 20 | 2018 |
| FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms Y Bécouarn, L Cany, M Pulido, R Beyssac, P Texereau, V Le Morvan, ... BMC research notes 7, 1-10, 2014 | 19 | 2014 |
| Predictive factors of 5-year relapse-free survival in HR+/HER2-breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials F Lerebours, M Pulido, E Fourme, M Debled, V Becette, H Bonnefoi, ... British journal of cancer 122 (6), 759-765, 2020 | 18 | 2020 |
| First-line systemic treatment with palbociclib in women aged≥ 70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program. E Carola, M Pulido, C Falandry, E Paillaud, P Caillet, L Tassy, M Bringuier, ... Journal of Clinical Oncology 41 (16_suppl), 1018-1018, 2023 | 17 | 2023 |
| Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue … M Spalato-Ceruso, F Bouteiller, JP Guegan, M Toulmonde, A Bessede, ... Journal of Hematology & Oncology 15 (1), 157, 2022 | 16 | 2022 |
carine belleraInstitut Bergonié, Comprehensive Cancer Center, Bordeaux; INSERM Bordeaux Population Health U1219Zweryfikowany adres z bordeaux.unicancer.fr
